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During the past few decades, a large number of animal studies demonstrated that commonly used opioids 
could provide cardioprotection against ischemia-reperfusion (I/R) injury. Opioid-induced preconditioning or 
postconditioning mimics ischemic preconditioning (I-Pre) or ischemic postconditioning (I-Post). Both δ- and 
κ-opioid receptors (OPRs) play a crucial role in opioid-induced cardioprotection (OIC). Down stream signaling 
effectors of OIC include ATP-sensitive potassium (KATP) channels, protein kinase C (PKC), tyrosine kinase, 
phosphatidylinositol-3-kinase (PI3-kinase), extracellular signal regulated kinase1/2 (ERK1/2), glycogen synthase 
kinase-3β (GSK-3β), and mitochondrial permeability transition pore (MPTP), among others. Recently, various 
reports also suggest that opioids could provide cardioprotection in humans. This review will discuss OIC using mostly 
morphine and remifentanil which are widely used during cardiac anesthesia in addition to the clinical implications 
of OIC. (Korean J Anesthesiol 2011; 61: 358-366)
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Introduction
It is well-established that ischemic preconditioning (I-Pre) 
and ischemic postconditioning (I-Post) are explicitly cardio-
protective strategies. The signaling pathways of I-Pre and 
I-Post are becoming increasingly clear. I-Pre, a series of brief 
ischemia-reperfusion (I/R) cycles before index ischemia, 
confers resistance against a subsequent prolonged period of 
myocardial ischemia. The cardioprotective mechanisms of I-Pre 
involve autacoid factors [1], protein kinase C (PKC) [2], reactive 
oxygen species [3], reperfusion injury salvage kinases [4], 
glycogen synthase kinase-3β (GSK-3β) [5] and mitochondrial 
permeability transition pore (MPTP) [6], among others. I-Post, 
which involves brief episodes of I/R during early reperfusion, 
is also a powerful strategy to limit reperfusion injury. The 
cardioprotection by I-Post may share common pathways with 
I-Pre including recruitment of signal transduction pathways [7]. 
However, there might be limitations to clinical use of I-Pre and 359 www.ekja.org
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I-Post. Indeed, I-Pre depends crucially on intervening before 
the ischemic event, and it is difficult to predict the onset of 
acute myocardial infarction. In addition, debates on the precise 
I-Post algorithm to use in clinical settings are ongoing. In this 
regard, pharmacological strategies are possible alternative 
methods and may provide a feasible means of effectively 
producing cardioprotection clinically. During the last 2 decades, 
pharmacological preconditioning and postconditioning to 
reduce myocardial I/R injury have been extensively studied. A 
number of cardioprotective ligands, including erythropoietin 
[8], adenosine [9], bradykinin [10], statins [11] and opioids [12], 
have been identified. Among them opioids are particularly 
interesting ligands to anesthesiologists because they are widely 
used during general anesthesia including cardiac anesthesia. 
In this review, we will discuss the cardioprotective outcomes 
in animal experiments and human studies that used opioids, 
particularly morphine and remifentanil which are currently 
commonly used for cardiac anesthesia. 
Evidence of involvement of opioid receptors 
(OPRs) in I-Pre and I-Post
After the concept of I-Pre was first described in 1986 by 
Murry et al. [13], a number of investigators have demonstrated 
that OPRs are involved in the mechanism of I-Pre-induced 
cardioprotection. Schultz et al. [14] first reported that OPRs play 
an important role in I-Pre in rat hearts. The infarct reducing 
effect by I-Pre elicited by three cycles of 5-min occlusion 
and reperfusion before 30 min ischemia was totally blocked 
by the nonselective OPR antagonist naloxone. One year 
later, Chien and Van Winkle [15] also demonstrated that the 
infarct limitation effect by I-Pre was blocked by (-)naloxone 
hydrochloride intravenously administered 25 min before index 
ischemia in open-chest rabbits. In addition, Schultz et al. [16] 
proposed that the cardioprotective effect by I-Pre was mediated 
by peripheral OPRs. In open-chest rat hearts, a high dose of 
naloxone methiodide which does not cross the blood-brain 
barrier antagonized the infarct sparing effect by I-Pre in their 
study. Taken together, these results strongly suggest that I-Pre-
induced cardioprotection is likely to be OPR-mediated. 
Meanwhile, there is evidence that I-Post-induced cardio-
protection also involves the activation of OPRs. Zatta et al. [17] 
demonstrated that I-Post with 3 cycles of 10 sec reperfusion and 
10 sec reocclusion at reperfusion onset increases endogenous 
cardiac opioids and activates local OPRs in anesthetized rat 
hearts. In addition, Jang et al. [18] reported that myocardial 
infarct size could be reduced by I-Post induced by six cycles of 
10 sec reperfusion and 10 sec occlusion started immediately 
after reperfusion in both open and isolated rat hearts. They 
additionally reported that the infarct-reducing effect by I-Post 
was totally blocked by naloxone and the δ-OPR antagonist 
naltrindole. These results highly suggest that endogenous 
opioid peptides and OPRs are involved in the cardioprotective 
phenomenon of I-Post.
Opioid peptides and OPRs 
It has been well known that opioid peptide synthesis, storage 
and release can take place in myocardial cells. Endogenous 
opioid peptides are synthesized and released after myocardial 
stres such as hypoxia or ischemia. The three distinct families 
of endogenous opioid peptides, enkephalins, dynorphins, and 
endorphins, are derived from three separate prohormones, 
proenkephalin, prodynorphin, and proopiomelanocortin, 
respectively. The enkephalins are considered important 
endogenous opioid peptides responsible for cardioprotection. 
It has been proposed that the increase in levels of enkephalins 
in infarcted ventricular tissue may counteract catecholamines 
released during ischemia and may be a defense mechanism to 
minimize the size of myocardial infarction [19]. 
The OPRs have been shown to mediate and regulate 
cardiovascular system function. OPRs are present centrally 
(hypothalamus and brainstem) and peripherally (cardiac 
myocytes, nerve terminals and adrenal medulla). The 
OPR family comprises three primary subtypes, μ-, δ-, and 
κ-OPRs. Among them, δ- and κ-OPRs are present on adult 
ventricular myocytes of the rat [20], even though μ- and 
κ-OPRs are present in neonatal rat hearts [12]. The δ-OPRs 
have the highest affinity for enkephalins whereas κ-OPRs bind 
preferentially to dynorphins. These OPRs belong to the family 
of guanine nucleotide binding protein (G-protein)-coupled 
receptors (GPCRs) which are cell surface proteins that convert 
extracellular stimuli into cellular signals. 
The δ- and κ-OPR subtypes include δ1-, δ2-OPRs and 
κ1-, κ2-OPRs, respectively. Multiple lines of evidence reveal 
that δ-OPRs, especially δ1-OPRs, play an important role in 
cardioprotection [16,21]. Schultz and colleagues [16] suggested 
that the cardioprotective effect by I-Pre was mediated via 
δ-OPRs because pre-administered naltrindole completely 
abolished the cardioprotective effect induced by I-Pre. 
Furthermore, this group also showed that δ1-OPRs play an 
important role in the cardioprotection of I-Pre because the 
selective δ1-OPRs antagonist 7-benzylidenenaltrexone (BNTX) 
but not the selective δ2-OPRs antagonist naltriben given before 
I-Pre significantly attenuated the infarct size by I-Pre [21]. I-Post 
also involves δ-OPR activation because there is evidence that 
the infarct-reducing effect by I-Post was totally blocked by 
naltrindole [18], as mentioned above.
Meanwhile, the cardioprotective role of κ-OPRs is less well 
characterized than that of δ-OPR and controversy continues 360 www.ekja.org
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regarding its role in myocardial I/R injury [21,22]. Schultz et 
al. [21] tested if the κ-OPR antagonist nor-binaltorphimine 
(nor-BNI) administered before I-Pre could block the anti-
infarct effect of I-Pre in open-chest rat hearts. The high dose 
of BNTX significantly attenuated the cardioprotective effect of 
I-Pre while nor-BNI did not. They demonstrated that δ1-OPRs 
but not κ-OPRs play an important role in the cardioprotective 
effect of I-Pre in the rat heart. Wang et al. [23] proposed that 
κ-OPRs mediats the ameliorating effects of I-Pre on infarct 
and arrhythmia, whereas δ-OPRs mediates the effects only 
on infarct because nor-BNI but not naltrindole reduced 
both infarction and arrhythmia in I-Pre with two cycles of 5 
min regional ischemia followed by 5 min reperfusion. Taken 
together, one can not completely rule out a role of κ-OPRs in 
cardioprotection.
Meanwhile, the role of μ-OPRs against myocardial I/R 
remains unclear because results of radioligand binding studies 
have disputed the presence of μ-OPRs in the myocardium. 
However, many studies that used morphine, which has a 
preference for μ-OPRs, showed a successful reperfusion 
mimetic. Actually, the lower dose of morphine seems to 
activate μ-OPRs but not δ- or κ-OPRs. Weihrauch et al. [24] 
demonstrated that morphine at reperfusion could reduce 
myocardial infarct size in rabbit hearts. Zatta et al. [17] 
suggested that the cardioprotective effect of I-Post appeared 
to involve endogenously activated μ-OPRs because the infarct 
sparing-effect by I-Post was abrogated by the potent μ-OPR 
antagonist CTAP administered at reperfusion in rat hearts. 
Therefore, it is plausible that μ-OPRs also may be involved in 
the cardioprotective mechanism. 
Exogenous activation of OPRs targeting 
ischemia
Over the past decade, accumulating evidence demonstrates 
that exogenous activation of OPRs confers cardioprotection. 
Exogenous administration of the naturally occurring opioid 
peptide Met5-enkephalin via osmotic minipump for 24 h limits 
myocardial infarction in anesthetized open-chest rabbits [25]. 
Schultz's group [26] first reported the cardioprotection by 
exogenously administered opioid. In their study, the exogenous 
pre-ischemic administration of morphine in three 5-min 
infusions interspersed with 5 min morphine-free periods before 
prolonged coronary occlusion significantly limited infarct size 
after myocardial I/R in open-chest rat hearts. Fryer et al. [27] 
demonstrated that exogenous application of the selective δ1-
OPRs agonist TAN-67 15 min before index ischemia significantly 
reduced infarct size in open-chest rats. In addition, there is 
evidence that exogenous activation of δ- and κ-OPRs affords 
protection against myocardial stunning in isolated murine 
hearts. The δ-OPRs agonist BW373U86 and the κ-OPRs agonist 
U50,488H (trans-(±)-3-dichloro-N-methy-N-[2-(1-pyrrolidinyl)
cyclohexyl]benzeneacetamide hydrochloride) administered 
for 10 min prior to global normothermic ischemia markedly 
improved post-ischemic contractile recovery as measured by 
left ventricular developed pressure (LVDP) [28]. Meanwhile, 
previous studies have demonstrated that exogenous activation 
of κ-OPRs with bremazocin increased myocardial infarction and 
another κ-OPRs agonist U50,488H exacerbated I/R arrhythmias 
following coronary occlusion in isolated rat hearts [29]. However, 
Peart et al. [22] reported that the two different κ-OPRs agonists 
U50,488H and ICI204,448 administered 10 min before the onset 
of ischemia significantly reduced infarct size in a similar extent 
as δ-OPRs activation by BW373U86. In addition, the κ-OPRs 
agonists also reduced arrhythmogenesis in their study. Recently, 
Maslov et al. [30] reported that peripheral δ2-OPRs activation 
by deltorphin II induced infarct size reduction in open-chest 
rat heart which suggests role for δ2-OPRs in cardioprotection. 
Taken together, these data verify that exogenous δ- and κ-ORs 
activation during ischemia indeed limited myocardial infarction 
and may improve functional recovery.
Exogenous activation of OPRs targeting 
reperfusion 
Recently, much research in myocardial I/R injury has shifted 
the paradigm from ischemic protection to reperfusion-mediated 
protection because pretreatment is seldom possible in acute 
myocardial infarction. It has been proposed that exogenous 
activation of δ-OPRs or κ-OPRs during the early reperfusion 
period confers cardioprotection to a similar extent as targeting 
the ischemic period. Exogenously applied BW373U86 admini-
stered 5 min before reperfusion mimicked the effect of 
I-Post or morphine-induced postconditioning in isolated rat 
hearts [18]. In addition, the δ-OPRs agonist [D-Ala2, D-Leu5] 
enkephalin (DADLE) started 5 min before reperfusion also 
reduced infarct size in rabbit hearts [31]. Meanwhile, Peart et 
al. [32] demonstrated that κ-OPR activation by U50,488H prior 
to reperfusion affords cardioprotection in both rat and mouse 
hearts. The infarct-reducing effect by U50,448H administered 
immediately prior to reperfusion was abolished by nor-BNI, 
given 10 min prior to reperfusion. U50,488H perfused 5 min 
before reperfusion significantly limited myocardial infarction 
and its mechanism was mediated by extracellular signal 
regulated kinase1/2 (ERK1/2) signaling pathway [33]. 
Morphine-induced cardioprotection in animals
Over the past decade, accumulating data demonstrate that 
pharmacological preconditioning and postconditioning with 361 www.ekja.org
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commonly used opioids, such as morphine and remifentanil, 
confer cardioprotection in animals. Morphine is frequently 
used for pain treatment during acute coronary syndromes. 
As mentioned above, Schultz's group [26] first reported that 
morphine-induced preconditioning (M-Pre) mimics I-Pre. 
Exogenously administered morphine before index ischemia 
could limit infarct size in rat hearts mediated via δ-OPRs 
because naltrindole completely abolished the cardioprotective 
effect induced by morphine [34,35]. M-Pre enhances isoflurane-
induced preconditioning in open-chest rat hearts [36]. The 
downstream signaling pathways of M-Pre involve KATP channels 
[26,37-39] and PKC [40]. 
Meanwhile, morphine-induced postconditioning (M-Post) 
also has a powerful cardioprotective effect, which seems to be 
similar to M-Pre or I-Post. Gross and co-workers [41] reported 
that M-Post limited infarct size in I/R-injured rat hearts. This 
group also demonstrated that the use of morphine and the 
opioid agonist methadone to manage acute and chronic pain 
could produce an infarct sparing effect in open-chest rat 
hearts [42]. Recently, Jang et al. [18] reported that the infarct 
sparing effect by M-Post was totally blocked by naltrindole 
in isolated rat hearts, implying the involvement of δ-OPRs in 
M-Post. More recently, Kim et al. [43] demonstrated that the 
involvement δ1-ORs in M-Post because the infarct limitation 
effect by M-Post was totally aborted by BNTX in isolated rat 
hearts (Fig. 1). Interestingly, however, Chen et al. [44] reported 
that infarct reducing effects by M-Post in isolated perfused rat 
hearts was significantly blocked by nor-BNI but not naltrindole, 
suggesting involvement of κ-OPRs but not δ-OPRs in M-Post. 
In their study, however, OPR antagonists, such as naloxone, 
naltrindole, and nor-BNI, also limited infarct size. Therefore, 
their results did not provide a clear distinction as to whether the 
infarct limitation effect by M-Post was caused by M-Post itself 
or by OPR antagonists. The proposed signaling mechanisms 
of M-Post involve nitric oxide [19], KATP channels [44,45], 
phosphatidylinositol-3-kinase (PI3-kinase) [24], GSK-β [41,46], 
mitochondrial-sensitive potassium channels [12], and MPTP 
[43]. For more detail on signaling pathways involved in opioid-
induced cardioprotection see the reference by Schultz and 
Gross [47].
Remifentanil-induced cardioprotection in 
animals
Remifentanil, the 4-anilidopiperidine derivative of fentanyl, 
also is a widely used opioid along with morphine during general 
anesthesia. Zhang et al. [48] first reported that remifentanil-
induced preconditioning (R-Pre) reduced myocardial infarct 
size in open-chest rat hearts. The infarct limiting effect by R-Pre 
was mediated via δ- and κ-OPRs. This group also demonstrated 
that PKC and mitochondrial KATP (mKATP) channels play an 
important role in R-Pre [49]. The cardioprotective mechanisms 
of R-Pre involve PKC, ERK1/2, and Akt pathways [50-52]. 
In addition, R-Pre produced delayed cardioprotection in 
anesthetized rat hearts and this effect was mediated via μ-, 
δ-, and κ-OPRs [53]. Furthermore, remifentanil-induced 
postconditioning (R-Post) also protects I/R induced hearts to 
a similar extent as I-Post which was mediated by both δ- and 
κ-OPRs [54] while ERK1/2 is involved in R-Post [55]. Meanwhile, 
remifentanil is a potent ultra short-acting synthetic opioid 
analgesic drug. Due to its rapid action, extremely short half-life, 
and rare cumulative effects, remifentanil is usually administered 
as a continuous infusion clinically. Therefore, it is worthwhile 
to determine whether remifentanil is protective only during 
preconditioning and postconditioning or remains protective 
when given continuously. However, controversy exists about 
the cardioprotective effect on continuous administration of 
remifentanil. Kuzume et al. [56] demonstrated that sustained 
administration of remifentanil before and throughout coronary 
occlusion did not result in protection of ischemic myocardium 
in intact rabbit hearts. However, Chun et al. [57] recently 
reported that continuous infusion of remifentanil targeting both 
ischemia and reperfusion could reduce infarct size in isolated 
rat hearts. The reports of pharmacological preconditioning and 
postconditioning with morphine and remifentanil in an isolated 
perfused heart, in vivo, in addition to those using cell culture 
models, are presented in Table 1. 
Fig. 1. Evidence for involvement of δ1-opioid receptors in morphine-
induced postconditioning (M-Post). Isolated rat hearts were 
subjected to 30 min regional ischemia and 120 min reperfusion. 
Morphine (1 μM) was perfused from 5 min before reperfusion to 
30 min after reperfusion. CON: untreated control hearts, NTD: 
δ-opioid receptors antagonist naltrindole, BNTX: δ1-opioid receptors 
antagonist 7-benzylidenenaltrexone. Infarct-limitation effect by 
M-Post was totally blocked by NTD and BNTX. *P < 0.05 vs. CON 
(Modified from Kim et al. [43] with permission). 362 www.ekja.org
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Functional recovery by morphine and remi-
fetanil against myocardial I/R injury
Usually, opioids have a negative chronotropic effect, i.e. 
decreasing heart rate (HR). M-Pre decreases HR after reper-
fusion in open-chest rat hearts compared to control hearts in 
open-chest rat hearts [58]. M-Post also decreases HR but has 
no significant difference in LVDP compared to control hearts 
[43]. R-Pre results in a decrease in HR, mean arterial blood 
pressure (MBP), and rate-pressure products (RPP) in open-
chest rat hearts [48,52] and R-Post and continuous infusion of 
remifentanil during myocardial I/R also significantly reduces 
HR [55]. Recently, Chun et al. [57] compared five different 
remifentanil-based strategies, including R-Pre, R-Post, ischemic 
targeting remifentanil, reperfusion targeting remifentanil, or 
both ischemic and reperfusion targeting remifentanil, against 
myocardial I/R injury. Interestingly, R-Pre better preserved 
LVDP, which is regarded as a contractility marker of the isolated 
rat heart, than various other remifentanil-based treatment 
strategies (Fig. 2). They demonstrated that the reason for that 
effect might be due to the pharmacology of remifentanil and/
or OPR responses. Namely, continuous infusion of remifentanil 
targeting only ischemia or only reperfusion may result in OPR 
desensitization and/or downregulation of OPR sensitization. 
Hemodynamic changes after reperfusion by opioids are 
variously reported according to animal models or ischemic 
severity. Even in the same experimental animal model with 
almost identical protocols, the hemodynamic results are 
occasionally conflicting. For example, Schultz et al. [35] demon-
strated that hemodynamic variables obtained for HR, MBP, 
and RPP by M-Pre were not significantly different compared to 
untreated control hearts in anesthetized rat hearts. However, 
another report by this group demonstrated that acute morphine 
treated-mice hearts showed significant improvement in 
Table 1. Cardioprotection by Exogenously Applied Morphine and Remifentanil in Animal Studies
Opioids Conditions  Model Involved OPR subtype(s) and mediators
Morphine 
Remifentanil
Pre
Post
Pre
Post
Intact rat heart
Intact rabbit heart
Isolated rabbit heart
Cardiomyocytes
Intact rat heart
Isolated rat heart
Intact rabbit heart
Isolated rat heart
Intact rat heart
Cardiomyocytes
Intact rat heart
δ-OPRs [37,41], KATP channels [26] 
δ-OPRs [33], PKC [39]
mKATP channels [36]
KATP channels [37], δ-OPRs [38], mKATP channels [38]
KATP channels [40,45], GSK [40,45], mKATP channels [44], mK(Ca) channels [12]
κ-OPRs [43], δ-OPRs [18], δ1-OPRs [42], mKATP channels [43], nitric oxide [18], MPTP [42]
PI3-kinase [24]
δ-OPRs [48], κ-OPRs [48], PKC [48], mKATP channels [48] 
μ-OPRs [47,52], δ-OPRs [47,52], κ-OPRs [47,52], ERK1/2 [49], PKC [51]
Akt [50]
δ-OPRs [53], κ-OPRs [53], ERK1/2 [54]
Pre: preconditioning, Post: postconditioning, OPR: opioid receptor, mKATP channels: mitochondrial KATP channels, PKC: protein kinase C, 
PI3-kinase: phosphatidylinositol-3-OH kinase, mK(Ca) channels: mitochondrial calcium-sensitive potassium channels, MPTP: mitochondrial 
permeability transition pore, ERK1/2: extracellular signal-regulated kinases, GSK: glycogen synthase kinase.
Fig. 2. (Top) Area at necrosis (AN) relative to percentage of area at risk 
(AR) as evaluated by triphenyltetrazolium chloride staining. (Bottom) 
Percentage recovery of left ventricular developed pressure (LVDP) after 
reperfusion in isolated rat hearts. CON: untreated control hearts, R-Pre: 
remifentanil preconditioning, R-Post: remifentanil postconditioning, 
R1: remifentanil targeting ischemia, R2: remifentanil targeting 
reperfusion, R3: remifentanil continuous infusion throughout 
ischemia and reperfusion. *P < 0.05 vs. CON (Modified from Chun et 
al. [57] with permission).363 www.ekja.org
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recovery of RPP and left ventricular end-diastolic pressure [59]. 
Infarct size is considered the gold standard measurement for 
myocardial I/R injury measurement. Functional recovery after 
reperfusion also is a highly plausible end point and is considered 
a sensitive one by some authors [60]. However, contractile 
dysfunction reflects a combination of the effects of stunning 
and cell death. In addition, the intraventricular balloon may be 
a less sensitive method for measurement of functional recovery. 
In this regard, it is suspicious that hemodynamic parameters 
may accurately reflect cardioprotective effects. Tissue salvaged 
by an anti-infarct intervention leads to improvement of 
cardiac function; however, infarct size limitation does not 
always produce mechanical functional recovery of hearts after 
myocardial I/R injury. There is evidence that I-Pre and I-Post 
limit infarct size but do not reduce myocardial dysfunction 
[61,62]. A potent opioid such as fentanyl also reduces infarct size 
but does not protect against myocardial dysfunction in isolated 
rat hearts [63]. The discrepancy between infarct size limitation 
and cardiac function recovery may be explained by continued 
stunning, i,e. prolonged myocardial dysfunction in the 
histological absence of necrosis after I/R injury. It is proposed 
that stunning occurs in reversibly injured cells or via nonlethal 
injury to the epicardial border zones surrounding infarcted 
myocardium. Although cellular ATP levels or free radicals have 
been proposed to be important mediators for stunning [64], 
the exact mechanism responsible remains unclear. Another 
possible mechanism for myocardial stunning is an increase in 
the concentration of intracellular Ca
2+ ([Ca
2+]). The increase in 
[Ca
2+] in myocardial cells likely explains the depressed ability of 
I/R hearts to generate contractile forces. 
Cross-talk between OPRs and adenosine 
receptors (ARs) 
Interestingly, the OPR family is known to 'cross-talk' with 
other GPCRs families, such as adenosine receptors (ARs). Kato 
et al. [65] reported that the improvement of post-ischemic 
mechanical function by fentanyl administered before induction 
of ischemia was abolished by the selective A1AR antagonist 
1,3-dipropyl-8-cyclopentylxanthine (DPCPX) in isolated rat 
hearts. They suggested the δ-OPR blockade inhibits A1ARs-
mediated protection. Peart and Gross [66] also demonstrated 
that there is a functional coupling between OPRs and ARs. 
The cardioprotection afforded by the A1ARs agonist 2-chloro-
cyclopentyladenosine or morphine was abolished by δ-OPRs 
antagonists BNTX or DPCPX, respectively, in anesthetized rat 
hearts. Taken together, it is likely that not only morphine but 
also remifentanil might 'cross talk' with ARs because these 
opioids activate δ-OPRs. Our recent unpublished data showed 
that the infarct-limiting effect by R-Post was significantly 
blocked by both naloxone and the nonspecific AR antagonist 
8-(p-Sulfophenyl)theophylline, implying 'cross-talk' between 
R-Post and ARs in isolated rat hearts. Meanwhile, there also is 
evidence for 'cross-talk' between OPRs and the β-adrenergic 
receptors (ADRs) system in the heart [67,68]. For details on 
'cross-talk' interactions between OPRs and β-ADRs in the heart, 
see the review by Pepe et al. [69]. 
Morphine- and remifentanil-induced cardio-
protection in humans
As a large number of studies performed in animals and 
cells strongly revealed that morphine- or remifentanil-induced 
preconditioning or postconditioning is cardioprotective, it 
should be determined if a similar effect is seen in the human 
heart. Growing evidence during recent years suggests that 
I-Pre and I-Post produce cardioprotection in animal as well as 
human hearts [70,71]. Tomai et al. [70] assessed whether the 
OPR antagonist naloxone abolishes adaptation to ischemia in 
humans during coronary angioplasty after repeated balloon 
inflations. In naloxone-treated patients, ST-segment change 
and cardiac pain severity during the second inflation were 
similar to those observed during the first inflation, whereas in 
placebo-treated patients, they were significantly lower. This 
finding reveals that I-Pre is mediated by OPRs in the human 
heart. Further more, I-Post also protects human hearts. I-Post 
performed immediately upon closing the lesion with guide 
wire and consisting of four cycles of 30 sec occlusion followed 
by 30 sec of reperfusion in patients undergoing primary 
coronary angioplasty resulted in reduction of infarct size, lower 
levels of creatine phosphokinase-myocardial band (CK-MB) 
fraction, and improved ejection fraction [71]. These beneficial 
effects persisted beyond 3 years. Bell et al. [72] reported that 
the expression of δ-OPRs in human atrial trabeculae isolated 
from patients undergoing coronary bypass grafting and δ-OPR 
stimulation mimicked I-Pre in human heart muscle in an 
hypoxic-reoxygenation model, which suggests a possible 
clinical use in myocardial ischemia treatment. 
Although many studies with morphine or remifentanil during 
cardiac procedures have mainly focused on hemodynamics, 
anesthetic requirement or postoperative analgesics require-
ment, several interesting reports have been published on a 
possible pharmacological approach with morphine and remi-
fentanil for the treatment of myocardial ischemia in clinical 
settings. Murphy and coworkers [73] administered 40 mg of 
morphine before cardiopulmonary bypass and evaluated the 
myocardial performance index with echocardiographic para-
meters intraoperatively. The myocardial performance index 
was improved by the administration of morphine prior to the 
ischemic insult of cardioplegic arrest. Pleym et al. [74] reported 364 www.ekja.org
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that 0.5 μg/kg/min remifentanil during coronary artery bypass 
graft in patients receiving remifentanil-isoflurane anesthesia 
reduced surgical stress but seemed to cause cardiac depression 
in the early postoperative phase. The patients who received 
supplemental remifentanil had a lower cardiac output, left 
ventricular stroke work index, and mixed venous oxygen 
saturation than placebo received patients. Recently, however, 
Xu et al. [75] reported that R-Pre decreased cardiac troponin I 
levels in patients undergoing off-pump coronary artery bypass 
surgery. R-Pre by 5 μg/kg of 10 min infusion after anesthetic 
induction markedly decreased the cardiac troponin I levels 
which is a high-specificity marker for cardiac injury after surgery 
compared to non-preconditioned patients. In addition, Wong et 
al. [76] reported that remifentanil administration 1 μg/kg bolus 
followed by a 0.5 μg/kg/min infusion for 30 min after anesthetic 
induction but before sternotomy yielded lower CK-MB levels in 
patients undergoing elective on-pump coronary bypass surgery. 
Summary
Morphine or remifentanil has been widely used periopera-
tively. A large number of in vitro and in vivo studies have 
demonstrated that morphine or remifentanil reliably offers 
cardioprotection. Both δ- and κ-ORs play a crucial role in 
morphine- or remifentanil-induced cardioprotection. The 
signaling pathways involved in the effects of these two opioids 
are currently being investigated; however, the cardioprotective 
effects of morphine or remifentanil in human hearts have not 
been fully examined yet. Further studies are needed to evaluate 
the effectiveness of morphine and remifentanil in a clinical 
setting.
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